adiponectin
Posted: Mon May 06, 2013 11:07 am
I've found a study on adiponectin:
What do you think about it?
I noticed that adiponectin was already mentioned in some posts but I'm creating separate thread for this topic.Eur J Immunol. 2013 May 3. doi: 10.1002/eji.201242836. [Epub ahead of print]
Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis.
Piccio L, Cantoni C, Henderson JG, Hawiger D, Ramsbottom M, Mikesell R, Ryu J, Hsieh CS, Cremasco V, Haynes W, Dong LQ, Chan L, Galimberti D, Cross AH.
Source
Department of Neurology, Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.
Abstract
Multiple Sclerosis (MS) is a presumed autoimmune disease directed against central nervous system (CNS) myelin, in which diet and obesity are implicated as risk factors. Immune responses can be influenced by molecules produced by fat cells, called adipokines. Adiponectin is an adipokine with anti-inflammatory effects. We tested the hypothesis that adiponectin has a protective role in the experimental autoimmune encephalomyelitis (EAE) model for MS, that can be induced by immunization with myelin antigens or transfer of myelin-specific T lymphocytes. Adiponectin deficient (ADPKO) mice developed worse EAE with greater CNS inflammation, demyelination and axon injury. Lymphocytes from myelin-immunized ADP KO mice proliferated more, produced higher amounts of IFN-γ, IL-17, TNF-α, IL-6 and transferred more severe EAE than wild type (WT) lymphocytes. At EAE peak, the spleen and CNS of ADPKO had fewer regulatory T (Treg) cells Treg cellsthan WT mice and during EAE recovery, Foxp3, IL-10 and TGF-β expression levels in the CNS were reduced in ADPKO compared with WT mice. Treatment with globular adiponectin (gADP) in vivo ameliorated EAE, and was associated with an increase in Treg cells. These data indicate that adiponectin is an important regulator of T-cell functions during EAE, suggesting a new avenue of investigation for MS treatment. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
PMID: 23640763 [PubMed - as supplied by publisher]
What do you think about it?